GO:0006163 purine nucleotide metabolic process: Biosynthesis, Salvage and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0006163 purine nucleotide metabolic process describes all chemical reactions and pathways involving purine nucleotides, including de novo synthesis, salvage, interconversion and degradation.
• Purine nucleotides are essential for DNA/RNA synthesis, energy transfer (ATP/GTP), signaling (cAMP/cGMP) and cofactor production (NAD, FAD, CoA) [1,8].
• Cancer cells reprogram purine metabolism to support rapid proliferation; both de novo and salvage pathways contribute to tumor growth [1,2].
• Key enzymes include PPAT, GART, PFAS, PAICS, ADSL, ATIC, IMPDH, HPRT1, APRT, ADA, PNP and FAMIN, which are potential therapeutic targets [1,3,8].
• CRISPR knockout, point mutation, knock-in and overexpression models enable functional dissection of purine metabolic genes in disease contexts [3,7].
• Understanding purine nucleotide metabolism is critical for developing therapies against cancer, immune disorders, and ischemia-reperfusion injury [2,4,6].
Description
Purine nucleotide metabolic process (GO:0006163) encompasses the chemical reactions and pathways involving purine nucleotides, which are composed of a purine base linked to a ribose or deoxyribose sugar and esterified with phosphate groups. These nucleotides are fundamental to all living cells, serving as building blocks for nucleic acids, energy carriers such as ATP and GTP, signaling molecules like cAMP and cGMP, and cofactors including NAD, FAD, and coenzyme A [1,8]. The process includes de novo synthesis from simple precursors, salvage pathways that recycle free bases, interconversion between different purine nucleotides, and degradation to uric acid [1,8]. Research into purine nucleotide metabolism has gained renewed attention due to its role in cancer, immune cell function, and tissue ischemia [1,2,4,6]. Tumors often exhibit altered purine metabolism to sustain rapid proliferation, with both de novo and salvage pathways contributing to nucleotide pools [1,2]. In immune cells, serine availability influences purine synthesis to support effector T cell expansion. Moreover, enzymes like FAMIN (also known as LACC1) have been shown to participate in a purine nucleotide cycle that modulates inflammasome activity. These findings highlight the importance of understanding the regulatory mechanisms and compartmentalization of purine metabolic enzymes [5,7]. This article provides a comprehensive overview of GO:0006163, covering its definition, biological significance, key genes, regulatory mechanisms, disease associations, and experimental approaches including CRISPR-based models. By integrating authoritative QuickGO annotations with verified PubMed literature, we aim to support researchers in designing robust studies on purine nucleotide metabolism.
purine nucleotide metabolic process At A Glance
| GO ID | GO:0006163 |
|---|---|
| GO term | purine nucleotide metabolic process |
| Ontology | biological_process |
| Synonym | purine metabolic process, purine metabolism, purine nucleotide metabolism |
| Major function | Synthesis, salvage, interconversion, and degradation of purine nucleotides |
| Key pathways | De novo purine biosynthesis, salvage pathway, purine nucleotide cycle |
| Cellular locations | Cytosol, mitochondria, peroxisomes |
| Related diseases | Cancer, immunodeficiency, gout, ischemia-reperfusion injury |
What Is GO:0006163?
According to the Gene Ontology, purine nucleotide metabolic process (GO:0006163) is defined as the chemical reactions and pathways involving a purine nucleotide, a compound consisting of a nucleoside (a purine base linked to a deoxyribose or ribose sugar) esterified with a phosphate group at either the 3' or 5'-hydroxyl group of the sugar. This process includes the biosynthesis, salvage, interconversion, and degradation of purine nucleotides such as AMP, GMP, IMP, and their deoxy derivatives.
Why Is purine nucleotide metabolic process Important in Cell Biology?
Purine nucleotide metabolism is essential for fundamental cellular processes, including DNA replication, RNA transcription, energy homeostasis, and signal transduction [1,8]. Dysregulation of this pathway is implicated in a wide range of human diseases, from cancer and autoimmune disorders to metabolic and cardiovascular conditions [1,2,3,6]. Understanding the enzymes and regulatory mechanisms involved provides opportunities for therapeutic intervention, as evidenced by ongoing efforts to target purine synthesis in small cell lung carcinoma and to modulate purine precursors in myocardial ischemia-reperfusion injury [2,6].
• Provides building blocks for DNA and RNA synthesis, critical for cell proliferation.
• Maintains cellular energy balance through ATP and GTP production.
• Supports signaling pathways via cAMP and cGMP.
• Enables synthesis of cofactors such as NAD, FAD, and coenzyme A.
• Dysregulated in cancer, supporting tumor growth and survival [1,2].
• Modulates immune cell function and inflammasome activity [3,4].
• Involved in ischemia-reperfusion injury and cardioprotection.
• Linked to inherited disorders like Lesch-Nyhan syndrome and gout.
• Target for antimetabolite drugs in chemotherapy and immunosuppression [2,8].
• Compartmentalization of enzymes affects cell motility and metastasis.
What Happens During purine nucleotide metabolic process?
De Novo Purine Biosynthesis
In simple terms: Cells build purine nucleotides from scratch using simple molecules like amino acids and sugars.
De novo purine biosynthesis converts phosphoribosyl pyrophosphate (PRPP) into inosine monophosphate (IMP) through a series of ten enzymatic steps. Key enzymes include PPAT, GART, PFAS, PAICS, ADSL, and ATIC. This pathway is energy-intensive and is tightly regulated to meet cellular demand. In tumors, de novo synthesis is often upregulated to support rapid proliferation [1,2]. The pathway occurs in the cytosol, with some steps requiring folate derivatives.
Salvage Pathway
In simple terms: Cells recycle free purine bases to make nucleotides, saving energy.
The salvage pathway recycles hypoxanthine, adenine, and guanine into IMP, AMP, and GMP, respectively, using enzymes such as HPRT1, APRT, and HGPRT [1,8]. This pathway is particularly important in tissues with low de novo synthesis, such as the brain and erythrocytes. Defects in salvage enzymes lead to disorders like Lesch-Nyhan syndrome and gout. Recent studies show that tumors can utilize both de novo and salvage pathways, with salvage contributing significantly in certain contexts.
Interconversion and Purine Nucleotide Cycle
In simple terms: Cells can convert one purine nucleotide into another to balance their pools.
Purine nucleotides can be interconverted through reactions catalyzed by enzymes like IMPDH, GMP synthase, and adenylosuccinate lyase [1,3]. The purine nucleotide cycle, involving AMP deaminase, adenylosuccinate synthetase, and adenylosuccinate lyase, plays a role in energy metabolism and ammonia production. FAMIN (LACC1) has been identified as a multifunctional enzyme enabling this cycle and regulating inflammasome activity.
Degradation
In simple terms: Cells break down purine nucleotides to uric acid for excretion.
Purine nucleotide degradation involves the sequential removal of phosphate and sugar moieties, ultimately producing uric acid in humans. Key enzymes include ADA, PNP, and xanthine oxidase. Disorders of purine degradation, such as ADA deficiency, cause severe immunodeficiency, while overproduction of uric acid leads to gout. The balance between synthesis and degradation is critical for cellular homeostasis.
Key Genes Involved in GO:0006163 purine nucleotide metabolic process
The following genes encode enzymes and regulators that are central to purine nucleotide metabolic process (GO:0006163).
| Gene | Major Role | Research Relevance |
|---|---|---|
| PPAT | First step of de novo purine biosynthesis | Target for cancer therapy; knockout reduces tumor growth |
| GART | Trifunctional enzyme in de novo pathway | Mutations cause neurological disorders; studied in cancer |
| PFAS | Formylglycinamidine ribonucleotide synthase | Essential for de novo synthesis; potential drug target |
| PAICS | Bifunctional enzyme in de novo pathway | Overexpressed in cancers; involved in metastasis |
| ADSL | Adenylosuccinate lyase | Deficiency causes adenylosuccinate lyase deficiency |
| ATIC | Bifunctional enzyme in de novo pathway | Target of antifolate drugs; studied in cancer |
| IMPDH | Inosine monophosphate dehydrogenase | Rate-limiting for GTP synthesis; target of mycophenolic acid |
| HPRT1 | Hypoxanthine phosphoribosyltransferase | Deficiency causes Lesch-Nyhan syndrome |
| APRT | Adenine phosphoribosyltransferase | Deficiency causes 2,8-dihydroxyadenine urolithiasis |
| ADA | Adenosine deaminase | Deficiency causes severe combined immunodeficiency |
| PNP | Purine nucleoside phosphorylase | Deficiency causes T-cell immunodeficiency |
| FAMIN (LACC1) | Multifunctional purine enzyme | Regulates purine nucleotide cycle and inflammasome |
| MTHFD2 | Mitochondrial folate enzyme | Links folate metabolism to purine sensing via mTORC1 |
| G6PD | Glucose-6-phosphate dehydrogenase | Provides NADPH for de novo synthesis |
| PRPS1 | Phosphoribosyl pyrophosphate synthetase | Mutations cause PRPS1 superactivity and gout |
| XDH | Xanthine dehydrogenase | Catalyzes terminal steps of purine degradation |
| SLC29A1 | Equilibrative nucleoside transporter | Uptake of nucleosides for salvage |
How Is purine nucleotide metabolic process Regulated?
Purine nucleotide metabolism is regulated at multiple levels to maintain cellular homeostasis. Allosteric feedback inhibition by end products (AMP, GMP, IMP) controls key enzymes such as PPAT and IMPDH. Transcriptional regulation responds to growth signals and nutrient availability, with mTORC1 sensing purine levels to drive differentiation. Compartmentalization of enzymes at the leading edge of motile cells suggests spatial regulation during migration. Additionally, serine availability influences purine synthesis in effector T cells, linking amino acid metabolism to nucleotide production. The purine nucleotide cycle, involving FAMIN, modulates inflammasome activity and cellular redox state.
purine nucleotide metabolic process and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| HPRT1 | Lesch-Nyhan syndrome | HPRT1 knockout mice, patient iPSCs |
| ADA | Severe combined immunodeficiency | ADA knockout mice, gene therapy models |
| FAMIN (LACC1) | Inflammatory bowel disease, autoinflammation | FAMIN knockout macrophages, colitis models |
| PAICS | Cancer metastasis | PAICS knockout cancer cell lines, xenografts |
| MTHFD2 | Cancer, differentiation | MTHFD2 knockout cells, mTORC1 reporter assays |
Cancer
Many cancers reprogram purine metabolism to support rapid proliferation. Small cell lung carcinoma exhibits metabolic hallmarks for purine nucleotide biosynthesis, with upregulation of de novo pathway enzymes. Both de novo and salvage pathways contribute to tumor nucleotide pools, and targeting these pathways can inhibit tumor growth. PAICS overexpression is associated with metastasis in various cancers.
Immunodeficiency and Autoimmunity
Defects in purine salvage enzymes cause severe immunodeficiencies. ADA deficiency leads to SCID, while PNP deficiency results in T-cell immunodeficiency. FAMIN (LACC1) mutations are linked to inflammatory bowel disease and autoinflammation through dysregulated purine nucleotide cycle and inflammasome activity. Serine metabolism supports effector T cell expansion by fueling purine synthesis, highlighting a link between nutrient availability and immune function.
Cardiovascular Disease
Purine nucleotide precursors have been investigated for preventing myocardial ischemia-reperfusion injury. Supplementation with purine precursors may enhance ATP recovery and reduce infarct size. The balance between purine synthesis and degradation influences cardiac energy homeostasis and oxidative stress.
Neurological and Metabolic Disorders
HPRT1 deficiency causes Lesch-Nyhan syndrome, characterized by neurological dysfunction and self-injurious behavior. APRT deficiency leads to kidney stones, and PRPS1 superactivity causes gout and deafness. Disorders of purine degradation, such as gout, result from uric acid overproduction.
From purine nucleotide metabolic process-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does gene X regulate de novo purine synthesis? | CRISPR knockout of gene X in cancer cell lines followed by metabolomics |
| What is the role of a specific point mutation in enzyme Y? | CRISPR point mutation knock-in in isogenic cell lines |
| How does overexpression of gene Z affect tumor growth? | CRISPR knock-in of inducible promoter or lentiviral overexpression |
| Where is enzyme W localized during cell migration? | CRISPR knock-in of fluorescent tag (e.g., GFP) and live imaging |
| Does gene V sense purine levels to regulate mTORC1? | CRISPR knockout of gene V and mTORC1 activity assays |
| Can purine precursors protect against ischemia-reperfusion injury? | In vivo mouse models with purine precursor supplementation |
How to Study the purine nucleotide metabolic process Process
| Method | What It Measures | Typical Application |
|---|---|---|
| LC-MS metabolomics | Steady-state levels of purine nucleotides | Profiling cancer cell lines and tumors |
| 13C/15N isotope tracing | Flux through de novo and salvage pathways | Determining pathway contributions in vivo |
| CRISPR knockout screens | Gene essentiality for purine metabolism | Identifying novel regulators |
| Fluorescence microscopy | Subcellular localization of enzymes | Studying compartmentalization during migration |
| Enzyme activity assays | Catalytic activity of purine enzymes | Characterizing mutations and inhibitors |
| Ribo-seq | Translation efficiency of metabolic genes | Assessing translational control |
| Proteomics | Protein expression levels | Validating knockout or overexpression |
| mTORC1 reporter assays | Purine sensing and signaling | Linking metabolism to growth control |
Metabolomics and Flux Analysis
Mass spectrometry-based metabolomics quantifies purine nucleotide levels and isotope tracing reveals flux through de novo and salvage pathways. This approach identifies metabolic vulnerabilities in cancer cells and tissues.
CRISPR Screening
Genome-wide CRISPR knockout screens can identify genes essential for purine nucleotide metabolism under specific conditions, such as nutrient deprivation or drug treatment. Hits can be validated with targeted knockouts.
Imaging and Compartmentalization
Fluorescent tagging of purine metabolic enzymes via CRISPR knock-in enables live-cell imaging to study spatial organization, such as localization at the leading edge of motile cells.
Biochemical Assays
Enzyme activity assays measure catalytic rates of purine metabolic enzymes using radiolabeled substrates or spectrophotometric methods [3,8]. These assays are used to characterize mutations and inhibitors.
How CRISPR Can Be Used to Study GO:0006163 purine nucleotide metabolic process
Knockout
CRISPR knockout of purine metabolic genes (e.g., PPAT, PAICS, HPRT1) in cell lines and animal models enables loss-of-function studies to assess their role in proliferation, survival, and disease progression [1,2]. Knockout models are also used to validate drug targets.
Point Mutation
CRISPR point mutation knock-in introduces specific amino acid substitutions to mimic patient mutations or to dissect catalytic residues. For example, mutations in HPRT1 or ADA can be modeled to study enzyme deficiency. This approach provides isogenic controls for precise functional analysis.
Knock-in
CRISPR knock-in of fluorescent tags (e.g., GFP) or epitope tags allows real-time tracking of enzyme localization and interactions. Knock-in of inducible promoters enables controlled overexpression for studying dose-dependent effects.
Overexpression
CRISPR-mediated overexpression via knock-in of a strong promoter or lentiviral delivery can model gene amplification observed in cancers. Overexpression of PAICS or IMPDH is used to study their oncogenic potential and drug resistance [1,2].
How EDITGENE Supports purine nucleotide metabolic process Research
Researchers studying purine nucleotide metabolic process-related genes often need to determine whether a candidate gene is causally involved in a specific phenotype, such as tumor growth, immune cell activation, or drug response. Generating precise genetic models is essential to establish causality and to validate therapeutic targets. EDITGENE provides a comprehensive suite of CRISPR services to accelerate this research.
Contact EDITGENE today to design your custom CRISPR model for purine nucleotide metabolic process research.
Frequently Asked Questions About purine nucleotide metabolic process
What is purine nucleotide metabolic process GO:0006163?
GO:0006163 is a Gene Ontology term describing the chemical reactions and pathways involving purine nucleotides, including their biosynthesis, salvage, interconversion, and degradation.
What genes are involved in purine nucleotide metabolism?
Key genes include PPAT, GART, PFAS, PAICS, ADSL, ATIC, IMPDH, HPRT1, APRT, ADA, PNP, and FAMIN (LACC1) [1,3,8].
Why is purine metabolism important in cancer?
Cancer cells reprogram purine metabolism to support rapid proliferation, and both de novo and salvage pathways contribute to tumor growth, making them potential therapeutic targets [1,2].
What diseases are associated with purine nucleotide metabolic process?
Disorders include Lesch-Nyhan syndrome, severe combined immunodeficiency, gout, inflammatory bowel disease, and ischemia-reperfusion injury [3,6,8].
How can CRISPR be used to study purine metabolism?
CRISPR knockout, point mutation, knock-in, and overexpression models enable functional studies of purine metabolic genes in disease contexts [1,3,7].
What is the role of FAMIN in purine metabolism?
FAMIN (LACC1) is a multifunctional purine enzyme that enables the purine nucleotide cycle and regulates inflammasome activity.
How is purine nucleotide metabolism regulated?
It is regulated by allosteric feedback, transcriptional control, mTORC1 signaling, and compartmentalization of enzymes [1,5,7].
What methods are used to study purine nucleotide metabolism?
Common methods include LC-MS metabolomics, isotope tracing, CRISPR screens, enzyme activity assays, and fluorescence imaging [1,5].
What is the purine nucleotide cycle?
The purine nucleotide cycle interconverts AMP, IMP, and adenylosuccinate, playing a role in energy metabolism and ammonia production.
Can purine precursors protect against heart attack damage?
Studies suggest that purine nucleotide precursors may prevent myocardial ischemia-reperfusion injury by enhancing ATP recovery.
Conclusion
Purine nucleotide metabolic process (GO:0006163) is a fundamental biological pathway that sustains DNA/RNA synthesis, energy balance, and signaling. Its dysregulation is implicated in cancer, immunodeficiencies, and cardiovascular diseases, making it a rich area for therapeutic targeting. Advances in CRISPR-based models and metabolomics continue to unravel the complexities of purine metabolism, offering new opportunities for drug discovery. EDITGENE's comprehensive services support researchers in generating precise genetic models to study this critical pathway.
References
- 1. Tran DH et al.. 2024. De novo and salvage purine synthesis pathways across tissues and tumors.. Cell 187(14):3602-3618.e20 PMID: 38823389
- 2. Tabata S et al.. 2024. Metabolic Hallmarks for Purine Nucleotide Biosynthesis in Small Cell Lung Carcinoma.. Mol Cancer Res 22(1):82-93 PMID: 37773022
- 3. Cader MZ et al.. 2020. FAMIN Is a Multifunctional Purine Enzyme Enabling the Purine Nucleotide Cycle.. Cell 180(2):278-295.e23 PMID: 31978345
- 4. Ma EH et al.. 2017. Serine Is an Essential Metabolite for Effector T Cell Expansion.. Cell Metab 25(2):345-357 PMID: 28111214
- 5. Wolfe K et al.. 2019. Dynamic compartmentalization of purine nucleotide metabolic enzymes at leading edge in highly motile renal cell carcinoma.. Biochem Biophys Res Commun 516(1):50-56 PMID: 31196624
- 6. Musial PT et al.. 2025. Purine Nucleotide Precursors in Preventing Myocardial Ischemia-Reperfusion Injury.. Int J Mol Sci 26(21) PMID: 41226492
- 7. Zarou MM et al.. 2024. Inhibition of mitochondrial folate metabolism drives differentiation through mTORC1 mediated purine sensing.. Nat Commun 15(1):1931 PMID: 38431691
- 8. Fox IH. 1981. Metabolic basis for disorders of purine nucleotide degradation.. Metabolism 30(6):616-34 PMID: 6262603
